Welcome to your
health care provider
Jublia Resource centre

Jublia bottle and box

Trust JUBLIA to treat onychomycosis.

JUBLIA is indicated for the topical treatment of mild to moderate onychomycosis (tinea unguium) of toenails without lunula involvement due to Trichophyton rubrum and Trichophyton mentagrophytes in immunocompetent adult patients.

Keep scrolling to learn more

Application tips

Remember:

  • A big toenail needs 2 applications once a day2
  • Each smaller toenail requires 1 application per day2

Apply Jublia2

  • ONCE DAILY (preferably at bedtime)
  • on CLEAN & DRY toenails
  • AFFECTED toenails only

Apply JUBLIA on affected toenails including:2

  • The cuticle (i.e., nail bed)

  • The folds of skin along the sides of the toenail (i.e., nail folds)

  • Underneath the end of the toenail (i.e., hyponychium)

Jublia bottle and box

Allow JUBLIA to dry for 10 minutes2

  • Allow treated areas to dry thoroughly before touching with bed sheets, socks or other clothing

Please consult the Product Monograph for full dosage and administration information.

Find out how many bottles your patient will need

TRY THE JUBLIA BOTTLE CALCULATOR

TRUST JUBLIA TO TREAT ONYCHOMYCOSIS

A ONCE-DAILY, TOPICAL SOLUTION
WITH DEMONSTRATED EFFICACY

Achieved efficacy in treating nail fungus, as defined by:2,3†

  • Mycologic cure‡ in 55.3% of patients vs. 16.8% with vehicle (52 weeks, p<0.001 secondary endpoint)
  • Complete cure§ in 18.8% of patients vs. 3.5% with vehicle (52 weeks, p<0.001)

At Week 12, mycologic cure rate data was observed: 24% of JUBLIA patients vs. 14% with vehicle†‡

Achieved healthy toenail growth measured at 5.0 mm vs. 1.5 mm with vehicle (52 weeks, p<0.001 secondary endpoint)†

Moderate case

Before and after week 52

40%
of affected toenail

0%
of affected toenail (Complete cure)§

Clinical photographs of two patients with moderate onychomycosis. Data on file. Results may not be representative of all patients.

Clinical use:
  • Safety and efficacy in patients under 18 or over 75 have not been studied.
  • Greater sensitivity of some older individuals (≥65) cannot be ruled out.
Relevant warnings and precautions:
  • Patients with a history or clinical signs of immunosuppression, HIV infection, uncontrolled diabetes, other toenail infection except Candida, toenail infection to the matrix, only lateral toenail disease, severe plantar tinea pedis.
  • Concomitant use of other antifungal therapy and daily use of JUBLIA for more than 48 weeks.
  • For topical use only, and only on toenails and immediately adjacent skin.
  • Flammable – keep away from heat or flame.
  • Sensitivity reaction or severe irritation.
  • Pregnant and nursing women.
For more information:

Please consult the Product Monograph for important information relating to adverse reactions, interactions, and dosing information, which have not been discussed in this piece. The Product Monograph is also available by calling 1-800-361-4261.

* Comparative clinical significance is unknown.

† A 48-week, randomized, double-blind, vehicle-controlled trials with 4-week post follow-up in 820 patients (618 JUBLIA, 202 vehicle) with 20–50% clinical involvement of area of target great toenail, without dermatophytomas or lunula (matrix) involvement. Patients not excluded for concomitant Candida infection.

‡ Defined as a negative fungal culture and a negative potassium hydroxide examination of target toenail sample

§ Defined as 0% clinical involvement of target toenail plus mycologic cure (primary endpoint).

¶ Defined as the change from baseline in the healthy (i.e. unaffected) target toenail measurement for the target toenail.

References:
  • IMS Brogan CompuScript Audit, September 2022.
  • JUBLIA Product Monograph. Bausch Health, Canada Inc.
  • Elewski BE, Rich P, et al. Efinaconazole 10% solution in the treatment of toenail onychomycosis: Two phaseIII multicenter, randomized, double-blind studies. J Am Acad Dermatol 2013;Vol 68, No 4:600-608.
Back to top arrow

Back to top